1. Home
  2. AMTB vs EVO Comparison

AMTB vs EVO Comparison

Compare AMTB & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amerant Bancorp Inc.

AMTB

Amerant Bancorp Inc.

HOLD

Current Price

$22.55

Market Cap

922.1M

Sector

Finance

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$2.76

Market Cap

934.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMTB
EVO
Founded
1979
1993
Country
United States
Germany
Employees
N/A
4553
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
922.1M
934.1M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
AMTB
EVO
Price
$22.55
$2.76
Analyst Decision
Buy
Strong Buy
Analyst Count
3
1
Target Price
$23.67
$7.00
AVG Volume (30 Days)
221.5K
95.9K
Earning Date
04-23-2026
04-08-2026
Dividend Yield
1.57%
N/A
EPS Growth
386.36
N/A
EPS
0.44
N/A
Revenue
N/A
N/A
Revenue This Year
$8.29
$1.37
Revenue Next Year
$7.67
$10.05
P/E Ratio
$50.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.62
$2.31
52 Week High
$24.38
$4.80

Technical Indicators

Market Signals
Indicator
AMTB
EVO
Relative Strength Index (RSI) 45.52 41.07
Support Level $21.98 $2.32
Resistance Level $22.75 $3.78
Average True Range (ATR) 0.55 0.09
MACD -0.12 -0.06
Stochastic Oscillator 32.16 19.16

Price Performance

Historical Comparison
AMTB
EVO

About AMTB Amerant Bancorp Inc.

Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: